Gilead expands liver disease pipeline with $4.3bn CymaBay acquisition pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for the .
TE Connectivity Ltd. (NYSE:TEL) Q1 2024 Earnings Call Transcript January 24, 2024 TE Connectivity Ltd. beats earnings expectations. Reported EPS is $5.76, expectations were $1.72. TE Connectivity Ltd. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, thank you for […]
Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) have been given a consensus recommendation of “Buy” by the thirteen ratings firms that are currently covering the company, MarketBeat reports. Twelve analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 […]